Market Price

6.58 

0.22 3.5%

as of Jun 02 '23

52 Week Range:

3.17 24.67


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 8.72
8.57
13.65
13.38
14.36
11.47
12.71
16.83
13.96
18.26
17.49
growth rate -1.7% 59.3% -2.0% 7.3% -20.1% 10.8% 32.4% -17.1% 30.8% -4.2%
Earnings BIT 11.43
3.05
11.66
-2.01
16.22
-49.95
-57.19
-40.87
-106.45
33.98
growth rate -73.3% 282.4% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE 49.26
285.71
185.19
-68.48
38.67
41.59
-28.53
-28.53
-28.53
49.39
49.39
growth rate 480.0% -35.2% -100.0% 100.0% 7.6% -100.0% 0.0% 0.0% 100.0% 0.0%
ROA 3.73
0.86
3.97
-0.69
3.61
-13.98
-15.89
-11.77
-19.90
9.08
-24.41
growth rate -76.9% 361.6% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROE 4.29
0.97
4.81
-0.86
4.19
-15.52
-18.04
-13.26
-23.33
19.27
-118.79
growth rate -77.4% 395.9% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROIC 3.76
0.91
4.72
-1.04
3.80
-15.69
-18.01
-13.24
-22.31
14.64
-60.63
growth rate -75.8% 418.7% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Cur. Ratio 6.51
11.74
11.48
9.86
10.93
8.04
7.14
8.47
4.93
6.02
3.98
growth rate 80.3% -2.2% -14.1% 10.9% -26.4% -11.2% 18.6% -41.8% 22.1% -33.9%
Quick Ratio 2.83
8.99
11.36
9.77
10.82
7.70
6.87
8.27
4.76
5.89
3.79
growth rate 217.7% 26.4% -14.0% 10.8% -28.8% -10.8% 20.4% -42.4% 23.7% -35.7%
Leverage 1.16
1.11
1.27
1.22
1.10
1.12
1.16
1.10
1.26
2.67
10.44
growth rate -4.3% 14.4% -3.9% -9.8% 1.8% 3.6% -5.2% 14.6% 111.9% 291.0%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 13.00
19.00
129.81
16.21
13.59
16.57
14.37
20.74
20.34
89.84
growth rate 46.2% 583.2% -87.5% -16.2% 21.9% -13.3% 44.3% -1.9% 341.6%
Acct.Payable 1.00
1.00
1.08
0.57
0.24
8.46
4.62
7.22
10.66
47.56
growth rate 0.0% 7.8% -47.2% -58.4% 3,468.4% -45.4% 56.1% 47.7% 346.4%
Cur.Assets 155.00
184.00
406.57
322.40
300.12
308.06
340.68
388.91
303.69
1,206.82
growth rate 18.7% 121.0% -20.7% -6.9% 2.7% 10.6% 14.2% -21.9% 297.4%
Total Assets 228.00
224.00
447.66
426.48
400.08
463.60
415.40
538.76
496.44
1,659.51
growth rate -1.8% 99.9% -4.7% -6.2% 15.9% -10.4% 29.7% -7.9% 234.3%
Cash 55.00
41.00
71.87
32.24
90.93
73.93
76.59
45.46
44.31
109.79
growth rate -25.5% 75.3% -55.2% 182.1% -18.7% 3.6% -40.6% -2.5% 147.8%
Inventory 3.00
1.00
0.73
0.56
0.37
0.31
0.30
0.25
0.29
9.96
growth rate -66.7% -26.9% -23.9% -33.7% -15.8% -3.1% -18.5% 17.5% 3,356.9%
Cur.Liabilities 24.00
16.00
35.41
32.70
27.47
38.30
47.70
45.92
61.56
200.46
growth rate -33.3% 121.3% -7.6% -16.0% 39.4% 24.5% -3.7% 34.1% 225.6%
Liabilities 31.00
22.00
95.51
77.67
37.34
48.14
56.73
50.39
101.74
1,038.19
growth rate -29.0% 334.1% -18.7% -51.9% 28.9% 17.8% -11.2% 101.9% 920.5%
LT Debt 0.10
0.10
0.30
0.25
0.23
0.22
0.09
0.07
272.76
growth rate 0.0% 198.6% -15.7% -10.6% -3.0% -59.8% -18.6% 6,076.4%
Equity 197.10
202.00
352.15
348.80
362.74
415.46
358.67
488.37
394.70
621.32
growth rate 2.5% 74.3% -1.0% 4.0% 14.5% -13.7% 36.2% -19.2% 57.4%
Common Shares 23.00
23.00
25.00
26.00
26.00
26.00
29.00
31.00
32.00
33.00
33.00
growth rate 0.0% 8.7% 4.0% 0.0% 0.0% 11.5% 6.9% 3.2% 3.1% 0.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 2.00
1.00
1.05
2.90
1.39
2.50
1.32
1.82
3.10
4.46
growth rate -50.0% 5.0% 176.3% -52.2% 80.5% -47.4% 38.2% 70.5% 43.6%
Cash Dividends 0.00 0.00
growth rate
Cash From OA 27.00
2.00
89.14
-14.22
-23.51
-46.62
-38.45
-32.78
-81.07
35.27
growth rate -92.6% 4,356.9% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
FCF per Share 1.16
-0.39
3.87
-1.35
-0.94
-1.89
-2.28
-0.51
-2.23
0.83
-12.59
growth rate -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Sale Purchase of Stock 135.55
115.37
115.37
115.37
growth rate -14.9% 0.0% 0.0%
FCF 23.00
-1.00
84.00
-35.00
-32.00
-50.00
-52.00
-36.00
-84.00
-14.00
-508.00
growth rate -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 82.00
52.00
77.96
63.98
106.22
49.74
66.79
76.44
71.76
327.70
growth rate -36.6% 49.9% -17.9% 66.0% -53.2% 34.3% 14.5% -6.1% 356.7%
Op.Income 8.00
2.00
11.66
-2.01
16.22
-49.95
-57.19
-40.87
-106.45
33.98
growth rate -75.0% 483.1% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0%
IBT 11.20
3.10
10.68
-4.31
20.63
-59.86
-68.79
-60.48
-106.52
22.49
growth rate -72.3% 244.6% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0%
Net Income 8.00
2.00
13.32
-3.01
14.90
-60.38
-69.83
-56.17
-103.01
97.89
growth rate -75.0% 566.1% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0%
EPS 0.36
0.08
0.54
-0.12
0.57
-2.28
-2.41
-1.79
-3.26
2.97
-15.40
growth rate -77.8% 575.0% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Gross Profit 82.00
52.00
77.96
63.98
106.22
49.74
66.79
74.65
59.67
318.52
growth rate -36.6% 49.9% -17.9% 66.0% -53.2% 34.3% 11.8% -20.1% 433.8%
R&D 55.90
37.70
47.85
51.85
74.93
83.82
103.45
87.21
106.78
125.40
growth rate -32.6% 26.9% 8.3% 44.5% 11.9% 23.4% -15.7% 22.5% 17.4%

Quarterly Statements

Item Name Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Earnings BIT -62.03
-72.84
-28.60
-71.36
-82.36
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Acct.Receivable 39.93
89.84
104.17
108.19
82.07
growth rate 125.0% 16.0% 3.9% -24.2%
Acct.Payable 74.43
47.56
124.30
134.66
168.40
growth rate -36.1% 161.4% 8.3% 25.1%
Cur.Assets 858.44
1,206.82
1,257.38
1,255.91
1,294.76
growth rate 40.6% 4.2% -0.1% 3.1%
Total Assets 1,380.15
1,659.51
1,649.91
1,577.41
2,883.94
growth rate 20.2% -0.6% -4.4% 82.8%
Cash 64.31
109.79
109.59
297.33
249.77
growth rate 70.7% -0.2% 171.3% -16.0%
Inventory 15.24
9.96
13.40
14.52
13.27
growth rate -34.6% 34.5% 8.3% -8.6%
Cur.Liabilities 170.88
200.46
202.26
204.55
259.12
growth rate 17.3% 0.9% 1.1% 26.7%
Liabilities 782.11
1,038.19
1,070.25
976.01
2,286.69
growth rate 32.7% 3.1% -8.8% 134.3%
LT Debt 272.76
275.19
277.68
280.22
growth rate 0.9% 0.9% 0.9%
Equity 598.04
621.32
579.65
601.41
597.25
growth rate 3.9% -6.7% 3.8% -0.7%
Common Shares 32.89
32.89
32.89
32.89
34.23
growth rate 0.0% 0.0% 0.0% 4.1%
Cash Flow Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Capital Expenditures 2.32
0.63
0.26
0.71
1.55
growth rate -73.0% -58.7% 174.8% 117.6%
Cash From OA -45.31
-69.18
-42.22
-89.36
-192.37
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -47.63
-69.81
-42.48
-90.08
-193.92
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Sales 22.00
36.04
47.19
38.23
41.24
growth rate 63.9% 30.9% -19.0% 7.9%
Op.Income -62.03
-72.84
-28.60
-71.36
-82.36
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -97.22
-36.72
-56.10
34.40
-154.01
growth rate 0.0% 0.0% 100.0% -100.0%
Net Income -65.34
-16.53
-41.61
20.89
-112.77
growth rate 0.0% 0.0% 100.0% -100.0%
EPS
growth rate
Gross Profit 18.27
26.63
42.14
28.10
33.76
growth rate 45.7% 58.3% -33.3% 20.2%
R&D 34.18
52.49
32.32
40.51
64.37
growth rate 53.6% -38.4% 25.3% 58.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (22.19)

YOY Growth Grade:

F (4.82)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 5.42 2.21 -54.89
EPS / Growth 75.9% 2.97 -41.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 17.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 9.1% 9.1%
Future PE 0.01 3.62 7.89
Future EPS 3.28 7.11 7.11
Value Price
MOS %
0.01
-99.9%
6.36
-3.4%
13.87
110.8%
MOS Price 0.00 3.18 6.93
IRT 2.18 1.94 1.94

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.